Veronia F. Fahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Veronia F. Fahim has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Amani Nabil Shafik
Medical Pharmacology Department, Faculty of Medicine, Cairo University, Cairo, Egypt and School of Medicine, Badya University, Giza, Egypt, Egypt
3 shared publications - Fady A. Iskander
School of Medicine, Badya University, Giza, Egypt, Egypt
3 shared publications - Hanaa S. Sallam
Department of Population Health and Health Disparities, Division of Global Partnerships, School of Public and Population Health, University of Texas Medical Branch at Galveston, Galveston, USA
3 shared publications - Hani Serag
Department of Population Health and Health Disparities, School of Public and Population Health, University of Texas Medical Branch, Galveston, TX 77555, USA
3 shared publications - Hassan A. Elsayegh
School of Medicine, Badya University, Giza, Egypt, Egypt
3 shared publications - Aboubaker M. Saleh
Faculty of Medicine, Cairo University, Cairo, Egypt, Egypt
1 shared publication
Latest Publications
- Open Access
- 9 March 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Pediatrics
- Vol. 15 (1)
Neonatal cholestasis is associated with cytochrome P450 1A2 detoxification defect: A single center pilot study
BACKGROUND Evidence supports that biliary atresia (BA) in Egyptian infants is an aflatoxin-induced cholangiopathy acquired perinatally in infants with glutathione S-transferase M1 deficiency: The Kotb disease BA variant. This inability to detoxify aflatoxins leads to progressive inflammatory adhesions and obliterative cholangiopathy early in life. AIM To investigate the cytochrome P450 1A2 (CYP1A2) detoxification enzyme levels in neonates with confirmed BA. METHODS This prospective descriptive analytical study estimated CYP1A2 detoxification enzyme levels using enzyme-linked immunosorbent assay in 20 neonates with confirmed BA. The level CYP1A2 was also estimated in a control group of 20 infants with neonatal hepatitis (NH) and 20 age- and sex-matched healthy infants. RESULTS The mean age at enrollment in the study was 2.16 ± 0.58 months, 2.51 ± 1.05 months and 1.9 ± 0.81 months for the BA, NH and control group (P = 0.42). The mean ± SD of CYP1A2 among BA, NH and control group was 13.58 ± 9.73, 9.59 ± 9.95 and 31.68 ± 12.33 (P = 0.001). Within 3 months of follow up, of those with BA who underwent portoenterostomy 12 (60%) had successful outcome and cleared the jaundice, 5 (25%) had a stationary course and did not clear the jaundice while 3 (15%) died. The cholestasis resolved in 5 (25%) of the NH group, and improved in 15 (75%). CYP1A2 level did not correlate with age (r = 0.1559, P = 0.336), or total bilirubin level (r = 0.156, P = 0.336), alanine aminotransferase (r = -0.166, P = 0.305), aspartate aminotransferase (r = 0.091, P = 0.576), gamma glutamyl transferase (r = -0.0027, P = 0.99), alkaline phosphatase (r = 0.1059, P = 0.515), or outcome (r = 1.565, P = 0.23). A low CYP1A2 predicted a susceptibility to cholestasis by logistic regression (P = 0.000, 95% confidence interval: 0.8224-0.9327). CONCLUSION Significantly low serum CYP1A2 was frequent among infants with BA and NH compared to the control group. The low serum CYP1A2 compromises the detoxification ability of neonates with cholestasis and may alter the pharmacokinetics of commonly used drugs. Careful consideration to drug dosing and toxicity risk should be given to those neonates. Further research on drug pharmacokinetics and detoxification in neonates with cholestasis is recommended.
- 9 March 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Pediatrics
- Vol. 15 (1)
Open AccessNeonatal cholestasis is associated with cytochrome P450 1A2 detoxification defect: A single center pilot study
BACKGROUND Evidence supports that biliary atresia (BA) in Egyptian infants is an aflatoxin-induced cholangiopathy acquired perinatally in infants with glutathione S-transferase M1 deficiency: The Kotb disease BA variant. This inability to detoxify aflatoxins leads to progressive inflammatory adhesions and obliterative cholangiopathy early in life. AIM To investigate the cytochrome P450 1A2 (CYP1A2) detoxification enzyme levels in neonates with confirmed BA. METHODS This prospective descriptive analytical study estimated CYP1A2 detoxification enzyme levels using enzyme-linked immunosorbent assay in 20 neonates with confirmed BA. The level CYP1A2 was also estimated in a control group of 20 infants with neonatal hepatitis (NH) and 20 age- and sex-matched healthy infants. RESULTS The mean age at enrollment in the study was 2.16 ± 0.58 months, 2.51 ± 1.05 months and 1.9 ± 0.81 months for the BA, NH and control group (P = 0.42). The mean ± SD of CYP1A2 among BA, NH and control group was 13.58 ± 9.73, 9.59 ± 9.95 and 31.68 ± 12.33 (P = 0.001). Within 3 months of follow up, of those with BA who underwent portoenterostomy 12 (60%) had successful outcome and cleared the jaundice, 5 (25%) had a stationary course and did not clear the jaundice while 3 (15%) died. The cholestasis resolved in 5 (25%) of the NH group, and improved in 15 (75%). CYP1A2 level did not correlate with age (r = 0.1559, P = 0.336), or total bilirubin level (r = 0.156, P = 0.336), alanine aminotransferase (r = -0.166, P = 0.305), aspartate aminotransferase (r = 0.091, P = 0.576), gamma glutamyl transferase (r = -0.0027, P = 0.99), alkaline phosphatase (r = 0.1059, P = 0.515), or outcome (r = 1.565, P = 0.23). A low CYP1A2 predicted a susceptibility to cholestasis by logistic regression (P = 0.000, 95% confidence interval: 0.8224-0.9327). CONCLUSION Significantly low serum CYP1A2 was frequent among infants with BA and NH compared to the control group. The low serum CYP1A2 compromises the detoxification ability of neonates with cholestasis and may alter the pharmacokinetics of commonly used drugs. Careful consideration to drug dosing and toxicity risk should be given to those neonates. Further research on drug pharmacokinetics and detoxification in neonates with cholestasis is recommended.
- Open Access
- 3 March 2026
- Published by MDPI AG in Preprints.org
Efficacy and Safety of Dexmedetomidine in the Prevention of Delirium in Intensive Care Units and Critically-Ill Old Adult Patients: A Systematic Review
Background/Objectives: Delirium is an acute state of confusion associated with impaired consciousness and a decline in cognitive function. Delirium has significant clinical importance due to its substantial impact on morbidity and mortality. The primary objective of this systematic review is to assess Dexmedetomidine’s potential efficacy for delirium in critically ill and elderly patients, addressing a significant need in this high-risk population, and to evaluate its safety as a secondary objective. Methods: A systematic review (2018–2024) searched PubMed, Embase, and Cochrane for English-language studies on dexmedetomidine and delirium in older intensive care unit (ICU) patients. Dual reviewers independently screened, extracted data, and resolved disagreements. Eligible randamized control trials (RCTs) and observational studies were assessed using Risk of Bias 2 ( RoB-2) and Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tools. Results: Dexmedetomidine emerges as a promising drug because of its unique pharmacological profile, which provides sedation without modulating gamma-aminobutyric acid (GABA) receptors, potentially lowering the risk of delirium. Its additional analgesic, anti-inflammatory, and organ-protective characteristics could provide broader clinical benefits in the ICU. However, the aged population’s heightened susceptibility to Dexmedetomidine’s hemodynamic effects may limit some of its potential benefits. Conclusions: Although existing research suggests short-term neuroprotective effects, these effects do not always translate into better long-term survival. As a result, further large-scale, well-designed randomized controlled trials are needed to determine the optimal use of Dexmedetomidine in this population and to understand its overall impact on morbidity and mortality in the ICU.
- 3 March 2026
- Published by MDPI AG in Preprints.org
Open AccessEfficacy and Safety of Dexmedetomidine in the Prevention of Delirium in Intensive Care Units and Critically-Ill Old Adult Patients: A Systematic Review
Background/Objectives: Delirium is an acute state of confusion associated with impaired consciousness and a decline in cognitive function. Delirium has significant clinical importance due to its substantial impact on morbidity and mortality. The primary objective of this systematic review is to assess Dexmedetomidine’s potential efficacy for delirium in critically ill and elderly patients, addressing a significant need in this high-risk population, and to evaluate its safety as a secondary objective. Methods: A systematic review (2018–2024) searched PubMed, Embase, and Cochrane for English-language studies on dexmedetomidine and delirium in older intensive care unit (ICU) patients. Dual reviewers independently screened, extracted data, and resolved disagreements. Eligible randamized control trials (RCTs) and observational studies were assessed using Risk of Bias 2 ( RoB-2) and Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tools. Results: Dexmedetomidine emerges as a promising drug because of its unique pharmacological profile, which provides sedation without modulating gamma-aminobutyric acid (GABA) receptors, potentially lowering the risk of delirium. Its additional analgesic, anti-inflammatory, and organ-protective characteristics could provide broader clinical benefits in the ICU. However, the aged population’s heightened susceptibility to Dexmedetomidine’s hemodynamic effects may limit some of its potential benefits. Conclusions: Although existing research suggests short-term neuroprotective effects, these effects do not always translate into better long-term survival. As a result, further large-scale, well-designed randomized controlled trials are needed to determine the optimal use of Dexmedetomidine in this population and to understand its overall impact on morbidity and mortality in the ICU.
- Open Access
- 24 November 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (23) , 3029
The Role of the Gut Microbiome Dysbiosis in Metabolic Dysfunction: A Mini Review
This review provides a comprehensive overview of the complex and dynamic bacterial composition of the human gastrointestinal (GI) microbiota and explores its integral role in the microbiome–gut–brain axis. It discusses the physiological and molecular pathways through which the gut microbiota communicates with the central nervous system, highlighting key barriers that can impede effective signaling along this axis. The review also delves into the influence of microbiota on brain health, including cognitive function, mood regulation, and neuroinflammation. It considers how disruptions in this system—known as dysbiosis—can contribute to metabolic and neurological dysfunction. The central focus of the article is the role of the commonly prescribed antidiabetic drug metformin, not only in regulating glucose metabolism but also in its emerging potential to beneficially modulate the gut microbiome. By doing so, metformin may indirectly support improved brain health. Ultimately, the article seeks to inform both healthcare practitioners and patients about the promising therapeutic implications of microbiome-targeted strategies, particularly metformin, in promoting cognitive and neurological well-being.
- 24 November 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (23) , 3029
Open AccessThe Role of the Gut Microbiome Dysbiosis in Metabolic Dysfunction: A Mini Review
This review provides a comprehensive overview of the complex and dynamic bacterial composition of the human gastrointestinal (GI) microbiota and explores its integral role in the microbiome–gut–brain axis. It discusses the physiological and molecular pathways through which the gut microbiota communicates with the central nervous system, highlighting key barriers that can impede effective signaling along this axis. The review also delves into the influence of microbiota on brain health, including cognitive function, mood regulation, and neuroinflammation. It considers how disruptions in this system—known as dysbiosis—can contribute to metabolic and neurological dysfunction. The central focus of the article is the role of the commonly prescribed antidiabetic drug metformin, not only in regulating glucose metabolism but also in its emerging potential to beneficially modulate the gut microbiome. By doing so, metformin may indirectly support improved brain health. Ultimately, the article seeks to inform both healthcare practitioners and patients about the promising therapeutic implications of microbiome-targeted strategies, particularly metformin, in promoting cognitive and neurological well-being.
- Open Access
- 29 September 2025
- Published by MDPI AG in Preprints.org
The Role of the Gut Microbiome Dysbiosis in Metabolic Dysfunction: A Mini Review
Objectives: This review provides a comprehensive overview of the complex and dynamic bacterial composition of the human gastrointestinal (GI) microbiota and explores its integral role in the microbiome-gut-brain axis. Methods: It discusses the physiological and molecular pathways through which the gut microbiota communicates with the central nervous system, highlighting key barriers that can impede effective signaling along this axis. The review also delves into the influence of the microbiota on brain health, including cognitive function, mood regulation, and neuroinflammation, and considers how disruptions in this system—known as dysbiosis—can contribute to metabolic and neurological dysfunction. Results: A central focus of the article is the role of the commonly prescribed antidiabetic drug Metformin, not only in regulating glucose metabolism but also in its emerging potential to beneficially modulate the gut microbiome. By doing so, Metformin may indirectly support improved brain health. Conclusions: Ultimately, the article seeks to inform both healthcare practitioners and patients about the promising therapeutic implications of microbiome-targeted strategies, particularly the use of Metformin, in promoting cognitive and neurological well-being.
- 29 September 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Role of the Gut Microbiome Dysbiosis in Metabolic Dysfunction: A Mini Review
Objectives: This review provides a comprehensive overview of the complex and dynamic bacterial composition of the human gastrointestinal (GI) microbiota and explores its integral role in the microbiome-gut-brain axis. Methods: It discusses the physiological and molecular pathways through which the gut microbiota communicates with the central nervous system, highlighting key barriers that can impede effective signaling along this axis. The review also delves into the influence of the microbiota on brain health, including cognitive function, mood regulation, and neuroinflammation, and considers how disruptions in this system—known as dysbiosis—can contribute to metabolic and neurological dysfunction. Results: A central focus of the article is the role of the commonly prescribed antidiabetic drug Metformin, not only in regulating glucose metabolism but also in its emerging potential to beneficially modulate the gut microbiome. By doing so, Metformin may indirectly support improved brain health. Conclusions: Ultimately, the article seeks to inform both healthcare practitioners and patients about the promising therapeutic implications of microbiome-targeted strategies, particularly the use of Metformin, in promoting cognitive and neurological well-being.
- Open Access
- 9 June 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Pediatrics
- Vol. 14 (2) , 100614
Drug prescribing pattern in upper respiratory tract infections among the pediatric population attending outpatient clinics in pediatric hospitals
BACKGROUND Upper respiratory tract infections (URTIs) are one of the most frequent causes of childhood school leave and morbidity. AIM To study the present trend of medications’ prescribing pattern utilized in URTIs among the pediatric population attending outpatient clinics in pediatric hospitals. METHODS This analytical observational cross-sectional research was conducted in 200 children aged 1–10 years with URTIs attending the pediatric outpatient clinics in pediatric hospitals, one of which is an educational hospital, from July 2018 to August 2020. RESULTS Most of the prescriptions in our study included antibiotics (116/58%). The most commonly prescribed antibiotic family was ampicillin/sulbactam or amoxicillin/clavulanic acid (53/26.5%), followed by first-generation cephalosporin (25/12.5%) and third-generation cephalosporin (20/10%). Macrolides and second-generation cephalosporins were prescribed less frequently, in 16 (8%) and 2 (1%) patients, respectively. Most of our study population (155/77.5%) was satisfied with their prescriptions, whereas the rest of the study population (45/22.5%) was unsatisfied. CONCLUSION Overprescription of antibiotics is a significant issue among clinicians in pediatric outpatient clinics. Stewardship of drugs, particularly antibiotics, is a must to prevent the development of drug resistance. Most cases of URTIs were treated in accordance with the existing national treatment guidelines.
- 9 June 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Pediatrics
- Vol. 14 (2) , 100614
Open AccessDrug prescribing pattern in upper respiratory tract infections among the pediatric population attending outpatient clinics in pediatric hospitals
BACKGROUND Upper respiratory tract infections (URTIs) are one of the most frequent causes of childhood school leave and morbidity. AIM To study the present trend of medications’ prescribing pattern utilized in URTIs among the pediatric population attending outpatient clinics in pediatric hospitals. METHODS This analytical observational cross-sectional research was conducted in 200 children aged 1–10 years with URTIs attending the pediatric outpatient clinics in pediatric hospitals, one of which is an educational hospital, from July 2018 to August 2020. RESULTS Most of the prescriptions in our study included antibiotics (116/58%). The most commonly prescribed antibiotic family was ampicillin/sulbactam or amoxicillin/clavulanic acid (53/26.5%), followed by first-generation cephalosporin (25/12.5%) and third-generation cephalosporin (20/10%). Macrolides and second-generation cephalosporins were prescribed less frequently, in 16 (8%) and 2 (1%) patients, respectively. Most of our study population (155/77.5%) was satisfied with their prescriptions, whereas the rest of the study population (45/22.5%) was unsatisfied. CONCLUSION Overprescription of antibiotics is a significant issue among clinicians in pediatric outpatient clinics. Stewardship of drugs, particularly antibiotics, is a must to prevent the development of drug resistance. Most cases of URTIs were treated in accordance with the existing national treatment guidelines.